ArticleDiscover oncology2025
Characterization of PANoptosis-based markers for ischemic stroke and their appealing implications in improving prognosis and in glioma patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivePyroptosis, apoptosis and necroptosis separately participate in the pathogenesis of ischemic stroke, but the implication of PANoptosis in this disease is still unexplored. This study conducted a comprehensive investigation on PANoptosis in ischemic stroke and glioma.
methodsFour transcriptomic datasets of ischemic stroke: GSE16561, GSE58294, GSE22255, and GSE37587 were gathered. Consensus clustering analysis was implemented based upon PANoptosis genes. WGCNA was utilized for PANoptosis subtyping-related genes. Multiple well-established machine learning models were also built for feature gene selection. Moreover, survival and receiver operating characteristic (ROC) analysis was performed to evaluated the prognostic value of the feature genes in the glioma.
resultsFifteen PANoptosis genes were aberrantly expressed in peripheral blood of ischemic stroke than that of controls. Based upon them, ischemic stroke was classified as two PANoptosis molecular subtypes, with heterogeneous molecular mechanisms, and immune cell infiltration. The PANoptosis molecular subtyping-related module genes were determined, and key genes were subsequently via distinct machine learning approaches. Among them, the SVM model had the lowest |residual|, and the AUC of 1 in diagnosing ischemic stroke. The feature genes in the SVM model were regarded as the key genes (comprising TMEM55A, CCPG1, CYP1B1, PJA2, MTPN, SCYL2, BAZ2B, and DPYD). Based upon them, the nomogram was established, which could accurately predict ischemic stroke risk. All of them were in relation to ischemic stroke-related signaling pathways, and immune cell infiltration. Transcription factors were predicted, which transcriptionally modulated them. Additionally, drugs that potentially targeted them were determined. Moreover, the expression and prognostic value of genes in glioma were evaluated in the The Human Protein Atlas (HPA) and The Cancer Genome Atlas database (TCGA). All genes showed a significant prognostic value except PJA2. The diagnostic and prognostic ROC analysis result indicated that BAZ2B can served as potential diagnostic and prognostic marker in glioma.
conclusionAltogether, this is the first study to characterize PANoptosis-based molecular subtypes, and diagnostic model for ischemic stroke, providing a promising avenue for patient risk prediction through a non-invasive method. Moreover, the BAZ2B genes could serve as predictive biomarkers in glioma, providing essential implications for patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.